[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 103
96. Tucker ON, Madhavan P, Healy V, Jeffers M, Keane FB: Unusual presentation of an appendiceal malignancy. Int Surg; 2006 Jan-Feb;91(1):57-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary malignant epithelial tumors of the appendix are uncommon.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Appendiceal Neoplasms / diagnosis
  • [MeSH-minor] Diverticulitis / diagnosis. Female. Humans. Intestinal Fistula / diagnosis. Middle Aged. Tomography, X-Ray Computed. Vaginal Fistula / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16706105.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


97. Sideris L, Mitchell A, Drolet P, Leblanc G, Leclerc YE, Dubé P: Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix. Can J Surg; 2009 Apr;52(2):135-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix.
  • BACKGROUND: Peritoneal carcinomatosis (PC) originating in the appendix is a rare disease for which the long-term prognosis is poor.
  • We used Ronnett's classification for tumour grading (disseminated peritoneal adenomucinosis = grade 0, peritoneal mucinous carcinomatosis with intermediate features = grade 1 and peritoneal mucinous carcinomatosis = grade 2).
  • [MeSH-major] Adenocarcinoma, Mucinous / therapy. Antineoplastic Agents / administration & dosage. Appendiceal Neoplasms / pathology. Hyperthermia, Induced. Peritoneal Neoplasms / therapy

  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Anat Pathol. 2005 Nov;12(6):291-311 [16330927.001]
  • [Cites] Jpn J Clin Oncol. 2005 Sep;35(9):531-5 [16027146.001]
  • [Cites] J Oncol Pharm Pract. 2005 Sep;11(3):111-9 [16390599.001]
  • [Cites] Br J Cancer. 2006 May 8;94(9):1287-92 [16622455.001]
  • [Cites] Am J Surg Pathol. 2006 May;30(5):551-9 [16699309.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):607-13 [16621432.001]
  • [Cites] Cancer Invest. 2006 Mar;24(2):154-9 [16537184.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):727-31 [10622499.001]
  • [Cites] Langenbecks Arch Surg. 1999 Dec;384(6):576-87 [10654274.001]
  • [Cites] J Chir (Paris). 1999 Dec;136(6):341-7 [10675825.001]
  • [Cites] Br J Surg. 2000 Aug;87(8):1006-15 [10931042.001]
  • [Cites] Ann Oncol. 2000 Nov;11(11):1477-83 [11142489.001]
  • [Cites] Gynecol Obstet Invest. 2001;51(2):73-80 [11223697.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):458-63 [11260116.001]
  • [Cites] Eur J Cancer. 2001 May;37(8):979-84 [11334722.001]
  • [Cites] Int J Surg Investig. 2000;1(5):431-9 [11341599.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):85-91 [11443613.001]
  • [Cites] Br J Surg. 2001 Aug;88(8):1130 [11488802.001]
  • [Cites] Int J Cancer. 2001 Oct 20;96(5):297-304 [11582582.001]
  • [Cites] Postgrad Med J. 2002 Mar;78(917):170-2 [11884702.001]
  • [Cites] Ann Oncol. 2002 Feb;13(2):267-72 [11886004.001]
  • [Cites] Tumori. 2002 Sep-Oct;88(5):370-5 [12487553.001]
  • [Cites] Gastroenterol Clin Biol. 2003 Apr;27(4):407-12 [12759682.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jul-Aug;13(4):413-8 [12911716.001]
  • [Cites] Eur J Surg Oncol. 2003 Oct;29(8):682-8 [14511618.001]
  • [Cites] Eur J Surg Oncol. 2004 Apr;30(3):280-5 [15028309.001]
  • [Cites] Br J Surg. 2004 Apr;91(4):455-6 [15048746.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1558-65 [15367418.001]
  • [Cites] Ugeskr Laeger. 2004 Aug 23;166(35):2979-81 [15387006.001]
  • [Cites] Dis Colon Rectum. 1987 Oct;30(10):772-9 [2820671.001]
  • [Cites] Cancer Res. 1989 Jun 15;49(12):3380-4 [2720692.001]
  • [Cites] Eur J Cancer Clin Oncol. 1989 Dec;25(12):1857-66 [2632267.001]
  • [Cites] Ann Surg. 1994 Feb;219(2):109-11 [8129480.001]
  • [Cites] Am J Surg Pathol. 1994 Jun;18(6):591-603 [8179074.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):29-42 [7826158.001]
  • [Cites] Cancer Treat Res. 1996;81:105-19 [8834579.001]
  • [Cites] Eur J Cancer. 1996 Sep;32A(10):1727-33 [8983281.001]
  • [Cites] J Cancer Res Clin Oncol. 1997;123(1):6-12 [8996534.001]
  • [Cites] Eur J Surg Oncol. 1997 Aug;23(4):317-21 [9315060.001]
  • [Cites] Rev Med Interne. 1997;18(10):769-75 [9500010.001]
  • [Cites] Semin Surg Oncol. 1998 Apr-May;14(3):254-61 [9548609.001]
  • [Cites] Anat Pathol. 1997;2:197-226 [9575376.001]
  • [Cites] Gastroenterologist. 1998 Jun;6(2):147-50 [9660531.001]
  • [Cites] Br J Surg. 1999 Jun;86(6):842 [10419331.001]
  • [Cites] Ned Tijdschr Geneeskd. 1999 Sep 11;143(37):1863-8 [10526600.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):300-8 [15650641.001]
  • [Cites] Clin Colorectal Cancer. 2005 Jan;4(5):296-9 [15663831.001]
  • [Cites] Zentralbl Chir. 2005 Apr;130(2):177-80 [15849666.001]
  • [Cites] Acta Chir Belg. 2005 Apr;105(2):127-33 [15906901.001]
  • [Cites] Hepatogastroenterology. 2005 May-Jun;52(63):812-6 [15966210.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):69-76 [16389186.001]
  • (PMID = 19399209.001).
  • [ISSN] 1488-2310
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 50SG953SK6 / Mitomycin; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC2663512
  •  go-up   go-down


98. Yantiss RK, Shia J, Klimstra DS, Hahn HP, Odze RD, Misdraji J: Prognostic significance of localized extra-appendiceal mucin deposition in appendiceal mucinous neoplasms. Am J Surg Pathol; 2009 Feb;33(2):248-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of localized extra-appendiceal mucin deposition in appendiceal mucinous neoplasms.
  • Appendiceal mucinous neoplasms confined to the mucosa are benign, whereas those with disseminated peritoneal mucin deposits often follow an indolent, but malignant, course.
  • Not infrequently, appendiceal mucinous neoplasms are associated with localized periappendiceal mucin deposits, but lack diffuse peritoneal involvement.
  • Mucin deposits in these cases may be acellular or contain neoplastic epithelium (cellular mucin).
  • Although some investigators consider both acellular and cellular periappendiceal mucin to pose no, or minimal, risk for recurrent disease, the biologic importance of localized extra-appendiceal mucin has never been evaluated.
  • We identified 65 patients with appendiceal mucinous neoplasms, all of whom had localized periappendiceal mucin deposits without diffuse peritoneal involvement, and assessed them for the presence of extra-appendiceal epithelium and clinical outcome.
  • Most (77%) cases showed acellular periappendiceal mucin, but 15 (23%) had scant extra-appendiceal epithelium (range: 1 to 12 cell clusters).
  • Upon follow-up (mean: 48 mo), 2 (4%) patients with acellular periappendiceal mucin developed diffuse peritoneal disease, but neither of these appendices was submitted in total for histologic evaluation.
  • In contrast, 5 of 15 (33%) patients with cellular periappendiceal mucin developed mucinous ascites, including 1 who eventually died of disease (P=0.03).
  • Thus, patients with appendiceal mucinous neoplasms and acellular periappendiceal mucin are unlikely to develop recurrent disease.
  • However, microscopic examination of the entire appendix is necessary, as lesions with extra-appendiceal tumor cells are more likely to progress to disseminated disease and result in death of the patient, even if the mucin is paucicellular and confined to the periappendiceal region.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Appendiceal Neoplasms / pathology. Mucins / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18852679.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


99. Vang R, Gown AM, Farinola M, Barry TS, Wheeler DT, Yemelyanova A, Seidman JD, Judson K, Ronnett BM: p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am J Surg Pathol; 2007 May;31(5):653-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas.
  • Distinction of primary ovarian epithelial tumors from metastatic adenocarcinomas is challenging for tumors exhibiting mucinous, endometrioid, or mixed endometrioid/mucinous differentiation.
  • Most endocervical adenocarcinomas exhibit mucinous and/or endometrioid differentiation; they infrequently metastasize to the ovaries but may simulate primary ovarian tumors [both atypical proliferative (borderline) and carcinoma].
  • The performance of this expression pattern for identifying metastatic endocervical adenocarcinomas in the ovaries among primary ovarian tumors and other metastatic adenocarcinomas having mucinous and/or endometrioid/endometrioidlike differentiation has not been evaluated.
  • Immunohistochemical expression of p16 was assessed in 195 tumors, including 98 primary ovarian tumors (51 mucinous, 47 endometrioid, and 4 mixed mucinous-endometrioid tumors), 93 metastatic adenocarcinomas of known primary sites (colorectum: 34, endocervix: 19, pancreaticobiliary tract: 17, appendix: 7, stomach: 5), 11 metastatic adenocarcinomas of unknown origin (7 established as noncervical), and 4 adenocarcinomas of uncertain (primary ovarian vs. metastatic) origin.
  • Mean and median expression values for HPV-positive endocervical adenocarcinomas (99%, 100%; range 90% to 100%) were substantially higher than those for primary ovarian mucinous (5%, 0%; range 0% to 70%) and endometrioid (20%, 10%; range 0% to 100%) tumors, HPV-unrelated endocervical adenocarcinomas (0%, 0%; range 0% to 60%), metastatic adenocarcinomas of unknown origin (11%, 0%; range 0% to 30%), and adenocarcinomas of uncertain (primary ovarian vs. metastatic) origin (40%, 35%; range 0% to 90%); only the 15 HPV-positive endocervical adenocarcinomas and 6 other tumors had values of 80% or greater.
  • Diffuse (>75% positive tumor cells) moderate to strong p16 expression is a sensitive (100%) and specific (97%) marker for identifying HPV-related endocervical adenocarcinomas metastatic to the ovary among the primary ovarian tumors and metastatic adenocarcinomas from other sites that are in the differential diagnosis of ovarian tumors having mucinous and/or endometrioid/endometrioidlike differentiation. p16 is useful as part of a panel of immunohistochemical markers for distinguishing primary ovarian tumors from metastases and, when diffusely positive, can suggest the cervix as a potential primary site for metastatic adenocarcinomas of unknown origin.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / metabolism. Carcinoma, Endometrioid / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Ovarian Neoplasms / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. DNA, Viral / analysis. Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Papillomaviridae / genetics. Papillomavirus Infections. Polymerase Chain Reaction


100. Pahlavan PS, Kanthan R: Goblet cell carcinoid of the appendix. World J Surg Oncol; 2005 Jun 20;3:36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Goblet cell carcinoid of the appendix.
  • BACKGROUND: Goblet cell carcinoid (GCC) of the appendix is a rare neoplasm that share histological features of both adenocarcinoma and carcinoid tumor.
  • This review summarizes the published literature on GCC of the appendix.
  • The focus is on its diagnosis, histopathological aspects, clinical manifestations, and management.
  • METHODS: Published studies in the English language between 1966 to 2004 were identified through Medline keyword search utilizing terms "goblet cell carcinoid," "adenocarcinoid", "mucinous carcinoid" and "crypt cell carcinoma" of the appendix.
  • RESULTS: Based on the review of 57 published papers encompassing nearly 600 diagnosed patients, the mean age of presentation for GCC of the appendix was 58.89 years with equal representation in both males and females.
  • Accurate diagnosis of this neoplasm requires astute observations within an acutely inflamed appendix as this neoplasm has a prominent pattern of submucosal growth and usually lacks the formation of a well-defined tumor mass.
  • Concomitant distant metastasis at diagnosis was present in 11.16% of patients with the ovaries being the most common site in 3.60% followed by disseminated abdominal carcinomatosis in 1.03%.
  • Local lymph node involvement was seen in 8.76% of patients at the time of diagnosis.
  • GCC's of the appendix remains a neoplasm of unpredictable biological behavior and thus warrants lifelong surveillance for recurrence of the disease upon diagnosis and successful surgical extirpation.
  • CONCLUSION: GCC of the appendix is a rare neoplasm.
  • Due to its wide range of presentation, this tumor should be considered as a possible diagnosis in many varied situations leading to abdominal surgery.
  • Histopathological features such as increased number of Paneth cells, increased amount of mucin secretion and presence of pancreatic polypeptide may predict a more aggressive behavior.
  • In female patients with GCC of the appendix regardless of age, bilateral salpingo-oophorectomy is advocated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1987 Feb;30(2):112-5 [3803115.001]
  • [Cites] Cancer. 1974 Mar;33(3):770-7 [4815580.001]
  • [Cites] Cancer. 1974 Aug;34(2):338-44 [4852178.001]
  • [Cites] Cancer. 1979 Nov;44(5):1700-6 [498041.001]
  • [Cites] Pathol Res Pract. 1984 Jul;178(6):555-61 [6483683.001]
  • [Cites] Gastroenterology. 1984 Feb;86(2):302-9 [6690357.001]
  • [Cites] Hum Pathol. 1982 Mar;13(3):286-8 [7076213.001]
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):188-9 [7102895.001]
  • [Cites] Acta Obstet Gynecol Scand. 1982;61(2):153-6 [7113691.001]
  • [Cites] Diagn Gynecol Obstet. 1980 Winter;2(4):269-74 [7215111.001]
  • [Cites] Am J Surg Pathol. 1981 Apr;5(3):213-24 [7235117.001]
  • [Cites] Cancer. 1978 Dec;42(6):2687-95 [728868.001]
  • [Cites] Cancer. 1978 Dec;42(6):2781-93 [728874.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1980;386(2):201-10 [7368563.001]
  • [Cites] Acta Morphol Acad Sci Hung. 1980;28(1-2):37-58 [7446221.001]
  • [Cites] J Clin Pathol. 1995 Sep;48(9):869-70 [7490325.001]
  • [Cites] Diagn Cytopathol. 1995 Feb;12(1):59-61 [7789249.001]
  • [Cites] Intern Med. 1994 Jul;33(7):422-6 [7949643.001]
  • [Cites] Am J Surg. 1994 Dec;168(6):685-7 [7978019.001]
  • [Cites] J Clin Pathol. 1977 May;30(5):473-80 [864014.001]
  • [Cites] Histopathology. 1995 Dec;27(6):557-62 [8838336.001]
  • [Cites] Int J Gynecol Pathol. 1996 Jan;15(1):85-8 [8852453.001]
  • [Cites] Am J Surg Pathol. 1997 Jan;21(1):109-13 [8990147.001]
  • [Cites] Arch Pathol Lab Med. 1976 Jun;100(6):301-6 [946758.001]
  • [Cites] J Gastroenterol. 1998 Aug;33(4):582-7 [9719248.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):815-21; discussion 822-3 [10363895.001]
  • [Cites] Cancer. 1999 Jul 1;86(1):14-21 [10391558.001]
  • [Cites] Eur J Surg. 1999 Oct;165(10):993-7 [10574110.001]
  • [Cites] Surg Today. 2000;30(1):78-81 [10648090.001]
  • [Cites] Arch Pathol Lab Med. 2001 Mar;125(3):386-90 [11231488.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):557-68 [11342766.001]
  • [Cites] Pathol Int. 2001 Apr;51(4):283-7 [11350611.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2001 Jul;97(1):90-5 [11435017.001]
  • [Cites] Eur J Surg Oncol. 2002 Mar;28(2):140-6 [11884049.001]
  • [Cites] Endocr Pathol. 2002 Spring;13(1):47-58 [12114750.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3307-12 [12115365.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):551-64 [12163380.001]
  • [Cites] Dig Dis Sci. 2002 Dec;47(12):2760-2 [12498298.001]
  • [Cites] Histopathology. 2003 Feb;42(2):137-40 [12558745.001]
  • [Cites] Surg Today. 2003;33(5):375-8 [12734735.001]
  • [Cites] Radiographics. 2003 May-Jun;23(3):645-62 [12740466.001]
  • [Cites] Br J Surg. 2003 Nov;90(11):1317-22 [14598408.001]
  • [Cites] Mod Pathol. 2003 Dec;16(12):1189-98 [14681318.001]
  • [Cites] Eur J Surg Oncol. 1992 Aug;18(4):386-7 [1521632.001]
  • [Cites] Am Surg. 2004 Jul;70(7):593-9 [15279181.001]
  • [Cites] Br J Surg. 2004 Sep;91(9):1168-73 [15449269.001]
  • [Cites] Diagn Cytopathol. 1991;7(2):155-7 [1648469.001]
  • [Cites] Histopathology. 1991 Jan;18(1):61-5 [1672861.001]
  • [Cites] Leber Magen Darm. 1991 Sep;21(5):226,229-30 [1758238.001]
  • [Cites] Br J Urol. 1976 Dec;48(6):436 [188508.001]
  • [Cites] Acta Pathol Jpn. 1991 Jun;41(6):455-60 [1950561.001]
  • [Cites] Am J Clin Pathol. 1990 Jul;94(1):27-35 [2163192.001]
  • [Cites] Arch Pathol Lab Med. 1979 Apr;103(4):180-2 [218519.001]
  • [Cites] Gut. 1990 Mar;31(3):322-4 [2323597.001]
  • [Cites] Gut. 1990 Jul;31(7):840 [2370022.001]
  • [Cites] Int Surg. 1989 Apr-Jun;74(2):109-10 [2753618.001]
  • [Cites] J Surg Oncol. 1988 Jan;37(1):65-71 [2826924.001]
  • [Cites] Arch Pathol Lab Med. 1985 Oct;109(10):930-3 [2994592.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1987;412(2):175-82 [3122418.001]
  • [Cites] Surg Gynecol Obstet. 1988 Jul;167(1):81-6 [3289135.001]
  • [Cites] Dis Colon Rectum. 1988 Aug;31(8):605-12 [3402286.001]
  • (PMID = 15967038.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1182398
  •  go-up   go-down






Advertisement